TABLE 2.
Mean percentages of leukocyte populations in PB and BFa
| Cell type | % Cell population
|
||||
|---|---|---|---|---|---|
| PB-NL (n = 5) | OspC-1
|
17-L
|
|||
| PB (n = 13) | BF (n = 13) | PB (n = 9) | BF (n = 9) | ||
| PMNd | 56.6 (46.9-66.4) | 46.2 (36.7-55.7) | 36.4 (26.3-46.4) | 42.6 (26.1-59.1) | 39.3 (27.3-51.3) |
| T cells | 24.4 (15.1-33.3) | 32.4 (23.8-41.0) | 30.02 (15.9-44.1) | 34.2 (23.5-44.8) | 25.1 (20.6-29.6) |
| Monocytes | 8.1 (5.1-10.9) | 8.7 (6.7-10.6) | 18.0 (10.5-25.5)c | 11.0 (8.3-13.6) | 18.6 (11.2-25.9)c |
| Plasma cells | 0.05 (0.03-0.07) | 0.02 (0.01-0.04) | 0.02 (0-0.05) | ND | ND |
| B cells | 2.5 (0-14.5) | 2.8 (1.1-4.4) | 0.5 (0.1-0.8) | 4.4 (0.2-8.5) | 0.8 (0.05-1.2) |
| Dendritic cells | 0.5 (0.3-0.6) | 0.4 (0.3-0.5) | 3.1 (1.9-4.2)bc | 0.4 (0.2-0.5) | 9.3 (3.4-15.2)c |
a
Comparison between healthy control PB (PB-NL) and PB and BF from subjects injected with either OspC-1 or 17-l. Numbers shown are mean percentages with 95% confidence intervals in parentheses.
b
Significantly different (P = 0.02), OspC-1 BF DCs versus 17-l BF DCs.
c
Significantly different (P < 0.05), BF versus PB.
d
Polymorphonuclear leukocytes.